RT Journal Article
SR Electronic
T1 Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.23.21268347
DO 10.1101/2021.12.23.21268347
A1 Coelho dos Reis, Jordana Grazziela A.
A1 Ferreira, Geovane Marques
A1 Lourenço, Alice Aparecida
A1 Ribeiro, Ágata Lopes
A1 Martins da Mata, Camila Pacheco da Silveira
A1 de Melo Oliveira, Patrícia
A1 de Almeida Marques, Daisymara Priscila
A1 Ferreira, Linziane Lopes
A1 Clarindo, Felipe Alves
A1 da Silva, Murillo Ferreira
A1 Póvoas Filho, Heitor Portella
A1 Oliveira Junior, Nilson Roberto Ribeiro
A1 D’Carmo Sodré, Maisah Meyhr
A1 Gadelha, Sandra Rocha
A1 Albuquerque, George Rego
A1 Maciel, Bianca Mendes
A1 Melo Mariano, Ana Paula
A1 de Melo Silva, Mylene
A1 Fontana, Renato
A1 Marin, Lauro Juliano
A1 Alberto Carlos, Renata Santiago
A1 Sampaio Lopes, Amanda Teixeira
A1 Ferreira, Fabrício Barbosa
A1 dos Santos, Uener Ribeiro
A1 de Santana, Íris Terezinha Santos
A1 Fehlberg, Hllytchaikra Ferraz
A1 Rezende, Rachel Passos
A1 Dias, João Carlos T
A1 Gross, Eduardo
A1 Castro Goulart, Gisele Assis
A1 Santiago, Marie Gabriele
A1 de Lemos, Ana Paula Motta Lavigne
A1 da Conceição, Aline O
A1 Romano, Carla Cristina
A1 de Carvalho, Luciana Debortoli
A1 Martins Filho, Olindo Assis
A1 Quadros, Claudio Almeida
A1 Valle, Sarah J
A1 Morris, David L
YR 2021
UL http://medrxiv.org/content/early/2021/12/23/2021.12.23.21268347.abstract
AB COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc®, a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic, antiviral, and anti-inflammatory effect of BromAc® in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation.Method Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine storm analysis was performed.Results BromAc® displayed a robust mucolytic effect in a dose dependent manner. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1RA and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250µg.Conclusion These results indicate robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill COVID-19 patients, indicating its potential as a therapeutic strategy to COVID-19.Competing Interest StatementSJV and DLM are employed by Mucpharm Pty Ltd and provided scientific input on the protocol and design of the study.Funding StatementMucpharm Pty Ltd financially supported this project. In addition, we thank all Brazilian funding agencies CAPES, CNPq and FAPEMIG for providing funding to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study followed the principles of Helsinki declaration as well as the resolution #466/2012 from the Brazilian Ministry of Health for research involving humans. This investigation was approved by the Santa Cruz State University (UESC) Institutional Brazilian Ethics Committee (Approval number: 45919121.6.0000.5526).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors